New Therapies for Geographic Atrophy
Veeral Sheth, MD discusses the two newly FDA-approved therapies for geographic atrophy: pegcetacoplan injection (SYFOVRE) and avacincaptad pegol (IZERVAY).
Symptoms and Manifestations of Geographic Atrophy
Veeral Sheth, MD, MBA describes the presentation of geographic atrophy in patients and how they are first affected by the disease.
Understanding Geographic Atrophy
David Lally, MD describes the hallmark features of geographic atrophy and how the disease develops over time.
Olivier Fakih, MD, MPH: Nationwide Data on Comorbidities of Axial Spondyloarthritis
This interview segment with Dr. Fakih featured a discussion about his team’s findings and their methodology on the topic of spondyloarthritis.
David Hunter, MBBS, PhD: Phase 3 Findings on Repeat TLC599 Injection for Osteoarthritis of the Knee
This discussion with Dr. Hunter covered the takeaways from his team’s phase 3 findings on treatment of osteoarthritis of the knee.
Ilias Alevizos, DMD, PhD: Safety, Future Development of Dazodalibep for Sjögren's Syndrome
During this interview segment, Dr. Alevizos discussed some of the implications of his team’s findings regarding dazodalibep.
Ilias Alevizos, DMD, PhD: Phase 2 Results on Dazodalibep for Sjögren's Syndrome
In this interview, Dr. Alevizos described the major takeaways from his team’s findings on this drug for Sjögren's Syndrome.
Women at 50% Greater Risk Progressing from Alcoholic Hepatitis to Cirrhosis than Men
Findings from The Liver Meeting show the impact of acute alcoholic hepatitis on progression to severe disease and risk of death among younger populations.
Jennifer Flemming, MD, FRCPC: Why Are More Women Developing Alcohol-Associated Liver Disease?
As more cases continue to disproportionately affect US women, an expert explains the biologic, sociocultural and clinical factors impacting the climb.
Prioritizing Gut Health, Bile Acid Research in Liver Disease Care
A trio of investigators discuss how research into bile acid interplay with the gut may lead to breakthroughs in treating conditions like NAFLD and NASH.
Bile Acids in Gut, Brain and Liver Health: What Do We Know?
A trio of scientists discuss the inception of a daylong Liver Meeting symposium around a little-understood subject in hepatic disease.
Jennifer I. Lim, MD: Effect of Faricimab on nAMD with Pigment Epithelial Detachments
Presented at AAO 2023, new data show dual Ang-2/VEGF-A inhibition with faricimab improved pigment epithelial detachment outcomes versus aflibercept.
Marco A. Zarbin, MD, PhD: Benefit of Faricimab for DME with BCVA ≤20/50
In a pooled subcohort analysis of YOSEMITE and RHINE, faricimab showed comparable vision outcomes with fewer injections than aflibercept in DME eyes with baseline BCVA of ≤ 20/50.
Julia A. Haller, MD: Disparities in Diabetic Macular Edema, Retinal Vein Occlusion Treatment
Patients who are female, in minority groups (particularly, Black or Asian), a visual acuity outside of the <20/40 to 20/200 range, and who are >70 years old receive less treatment.
Raj Chovatiya, MD, PhD: Efficacy, Safety of Secukinumab for Hidradenitis Suppurativa
In this segment of his interview, Dr. Chovatiya discussed some of the key safety data on secukinumab following the drug’s FDA approval for hidradenitis suppurativa.
What Does the FDA Approval of Secukinumab Mean for Patients with HS?
In this interview, Dr. Chovatiya responds to questions about the new FDA approval of secukinumab for patients with hidradenitis suppurativa.
Steven R. Feldman, MD, PhD: Asking Questions About Eczema Data, Disparities in Care
This interview with Dr. Feldman involved a discussion on new findings regarding atopic dermatitis patient preferences and racial disparities in dermatologic care.
Tralokinumab: Spotlighting the Recent Findings for Patients with Atopic Dermatitis
In this interview with Dr. Steven Feldman, the latest findings on tralokinumab-ldrm as an atopic dermatitis treatment were discussed.
What Would FDA Approval of Tapinarof Mean for Patients with Eczema?
In this discussion, Dr. Jeff Yu explores the topic of atopic dermatitis treatment news and the upcoming decision by the FDA on tapinarof for this skin disease.
Cheryl M. Burgess, MD: Answering Questions on Treatments for Skin of Color
In this Fall Clinical Dermatology Conference interview, Dr. Burgess answered several questions related to aesthetic treatments for patients with skin of color, including specific recommendations.
Better Fecal Live Microbiota Outcomes Linked to Gut Microbiome Health
New PUNCH CD3 analyses show patients who were treated with live fecal microbiota therapy improved their gut health at 8 weeks—which correlated with improved quality-of-life scores.
Paul Feuerstadt, MD: Preventing Recurrent C Difficile in Older Adults with Comorbidities
Feuerstadt reviews ACG 2023 data showing live microbiota therapy provides consistent protection against rCDI in one of the most vulnerable patient populations.
Brian Lacy, MD, PhD: Tailoring Treatment Experiences for IBS-C Patients
No catch-all drug works to treat irritable bowel syndrome with constipation. But as the Mayo Clinic expert explains, enough unique options exist to tailor care better than ever.
Jeff Yu, MD: Facts to Remember for Eczema Awareness Month
In this interview, Dr. Yu explains several important pieces of information regarding atopic dermatitis that he believes clinicians should be aware of.
Gestational Low-Dose Aspirin Does Not Increase Risk of IBD Flares in Women
Study author Uma Mahadevan, MD, discusses her team's findings suggesting the concern of IBD flare risk in pregnant women receiving aspirin to prevent preeclampsia is unwarranted.
Jiten P. Kothadia, MD: Using S-DAT to Reduce Alcohol Liver Disease Relapses
The study author discusses the clinical implications of his team's assessment into a risk factor score for alcohol relapse among post-transplant patients with ALD.
Tenapanor Provides Varied Timing for IBS-C Symptom Relief
Investigator Brian E. Lacy, MD, PhD discusses new post hoc analysis that he hopes will provided clearer expectations for timing of benefit with tenapanor.
Eingun James Song, MD: Improving Efficiency in Dermatology Offices
In his ‘Early Dermatology Practice Pearls’ presentation, Dr. Song described tips for dermatologists. In this interview segment, he continues this discussion.
Eingun James Song, MD: More Tips for Dermatology Office Workflow
Dr. Song spoke in this segment of his interview on several more insightful elements from his presentation titled ‘Early Dermatology Practice Pearls.’
S-DAT Score Predictive of Alcohol Relapse Risk in Liver Transplant Patients
Investigator Jiten P. Kothadia, MD, discusses the advent of a predictive score for alcohol relapse risk in patients with alcohol liver disease who received a liver transplant in the last year.